Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Head & Neck 3Dermatologic 3Myeloid 2Lymphoid 2CNS 2Breast 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 159Leukemia, Myeloid, Acute 141Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Myeloproliferative Disorders 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Primary Myelofibrosis 47Leukemia, Myelomonocytic, Chronic 40Lymphoma, Non-Hodgkin 36Leukemia 26Polycythemia Vera 23Hodgkin Disease 23Myelodysplastic-Myeloproliferative Diseases 21Multiple Myeloma 20Thrombocythemia, Essential 19Hematologic Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Neoplasms 17Leukemia, Biphenotypic, Acute 15Anemia, Refractory, with Excess of Blasts 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Recurrence 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11Medulloblastoma 11

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Soft Tissue Neoplasms × Myeloid × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04996875 2026-05-05

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
LymphoidMyeloidOther hematologic neoplasm

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡